Evolving role of rituximab in the treatment of patients with non-Hodgkin's lymphoma

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  Clarke CA, Glaser SL, Dorfman RF, Bracci PM, Eberle E, Holly EA: Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epid. Biomarkers Prev.13(1), 138–143 (2004).Crossref, Medline, Google Scholar
• 2  Cartron G, Watier H, Golay J, Solal-Celigny P: From the bench to the bedside: ways to improve rituximab efficacy. Blood104(9), 2635–2642 (2004).Review of the mechanisms of action of rituximab in lymphoma.Crossref, Medline, CAS, Google Scholar
• 3  Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A: Cytokine-release syndrome in patients with B cell chronic lymphocytic leukaemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood94(7), 2217–2224 (1999).Crossref, Medline, CAS, Google Scholar
• 4  Weng WK, Levy R: Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood98(5), 1352–1357 (2001).Crossref, Google Scholar
• 5  Clynes RA, Towers TL, Presta LG, Ravetch JV: Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med.6(4), 443–446 (2000).Crossref, Medline, CAS, Google Scholar
• 6  Cartron G, Dacheux L, Salles G et al.: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood99(3), 754–758 (2002).Crossref, Medline, CAS, Google Scholar
• 7  Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol.21(21), 3940–3947 (2003).Crossref, Medline, CAS, Google Scholar
• 8  Boettcher S, Pott C, Ritgen M, Hiddemann W, Unterhalt M, Kneba M: Evidence for Fcγ receptor IIIA-independent rituximab effector mechanisms in patients with follicular lymphoma treated with combined immunochemotherapy. Proc. Am. Soc. Hemat. Blood104, 170a[Abstract] (2004) .Google Scholar
• 9  Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B: Chimeric anti-CD20 (Idec-C2b8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother. Radiopharm.12(3), 177–186 (1997).Crossref, Medline, CAS, Google Scholar
• 10  Alas S, Bonavida B, Emmanouilides C: Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Antican. Res.20(5A), 2961–2966 (2000).Medline, CAS, Google Scholar
• 11  Alas S, Bonavida B: Rituximab inactivates signal transducer and activation of gtranscription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin-10 autocrine/paracrine loop and results in downregulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res.61(13), 5137–5144 (2001).Medline, CAS, Google Scholar
• 12  Ghetie MA, Bright H, Vitetta ES: Homodimers but not monomers of rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood97(5), 1392–1398 (2001).Crossref, Medline, CAS, Google Scholar
• 13  Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C, Bonavida B: Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene23(20), 3530–3540 (2004).Crossref, Medline, CAS, Google Scholar
• 14  Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22(47), 7359–7368 (2003).Review of the mechanisms of action of rituximab with emphasis of mechanisms of resistance to rituximab.Crossref, Medline, Google Scholar
• 15  Bohen SP, Troyanskaya OG, Alter O et al.: Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc. Natl Acad. Sci. USA100(4), 1926–1930 (2003).Crossref, Medline, CAS, Google Scholar
• 16  Grillo-Lopez AJ, Hedrick E, Rashford M, Benyunes M. Rituximab: Ongoing and future clinical development. Semin. Oncol.29(1 Suppl. 2), 105–112 (2002).Review of the development of rituximab treatment in lymphoma with emphasis on safety.Crossref, Medline, CAS, Google Scholar
• 17  Lim SH, Zhang Y, Wang Z et al.: Maintenance rituximab after autologous stem cell transplant for high-risk B cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplamt 35(2),207–208 [Abstract](2004).Google Scholar
• 18  Maloney DG: Preclinical and Phase I and II trials of rituximab. Semin. Oncol.26(5 Suppl. 14), 74–78 (1999).Medline, CAS, Google Scholar
• 19  McLaughlin P, Grillo-Lopez AJ, Link BK et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma – half of patients respond to a four-dose treatment program. J. Clin. Oncol.16(8), 2825–2833 (1998).First description of the benefit associated with rituximab treatment in relapsing or refractory patients with indolent lymphoma.Crossref, Medline, CAS, Google Scholar
• 20  Davis TA, Grillo-Lopez AJ, White CA et al.: Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: Safety and efficacy of retreatment. J. Clin. Oncol.18(17), 3135–3143 (2000).Crossref, Medline, CAS, Google Scholar
• 21  Lemieux B, Bouafia F, Thieblemont C et al.: Second treatment with rituximab in B cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. Hematol. J. 5(6), 467–471 (2004).Google Scholar
• 22  Berinstein NL, Grillo-Lopez AJ, White CA et al.: Association of serum rituximab (IDEC-C2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol.9(9), 995–1001 (1998)Crossref, Medline, CAS, Google Scholar
• 23  Ghielmini M, Schmitz SF, Cogliatti SB et al.: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood103(12), 4416–4423 (2004).First description of the benefit associated with prolonged treatment of rituximab, called maintenance.Crossref, Medline, CAS, Google Scholar
• 24  Hainsworth JD: Prolonging remission with rituximab maintenance therapy. Semin. Oncol.31(1 Suppl. 2), 17–21 (2004).Crossref, Medline, CAS, Google Scholar
• 25  Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA: Maximizing therapeutic benefit of rituximab: Maintenance therapy versus retreatment at progression in patients with indolent non-Hodgkin's lymphoma. A randomized Phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol. 23, 1088–1095 (2005).Google Scholar
• 26  Ardeshna KM, Smith P, Norton A et al.: Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet362(9383), 516–522 (2003).Crossref, Google Scholar
• 27  Colombat P, Salles G, Brousse N et al.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood97(1), 101–106 (2001).Crossref, Medline, CAS, Google Scholar
• 28  Hainsworth JD, Litchy S, Burris HA et al.: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J. Clin. Oncol.20(20), 4261–4267 (2002).Crossref, Medline, CAS, Google Scholar
• 29  Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J. Clin. Oncol. 4111–4116 (2004).Google Scholar
• 30  Marcus R, Imrie K, Belch A et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Proc. Am. Soc. Hemat. Blood 104, 1417–1423 [Abstract] (2004).First description of the benefit of R-CVP in untreated patients with follicular lymphoma.Google Scholar
• 31  Hiddemann W, Dreyling MH, Forstpointner R et al.: Combined immuno-chemotherapy (R-CHOP) significantly improves time to treatment failure in first-line therapy of follicular lymphoma results of a prospective randomized trial of the German low grade Lymphoma Study Group (GLSG). Blood102,104a [Abstract 352] (2003).Google Scholar
• 32  Herold M, Pasold R, Srock S et al.: Results of a prospective randomized open-label Phase III study comparing rituximab plus mitoxantrone, chlorambucil, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Blood104,169a [Abstract 584] (2004).Crossref, Google Scholar
• 33  Salles G, Foussard C, Mounier N et al.: Rituximab added to CHVP + IFN improves the outcome of follicular lymphoma patients: first analysis of the GELA-GOELAMS FL-2000 randomized trial. Blood104(11) [Abstract 160] (2004).Google Scholar
• 34  Hiddemann W, Dreyling M, Unterhalt M et al.: Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treament failure compared to CHOP alone in mantle cell lymphoma: results of a prospective ransomized trial of the German Low Grade Lymphomas Study Group. Proc. Am. Soc. Clin. Oncol. [Abstract 6501] (2004).Google Scholar
• 35  Forstpointner R, Dreyling M, Repp R et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas – results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood104, 3064–3071 (2004).First description of the benefit associated with R-chemotherapy in relapsing patients with indolent lymphoma; here the chemotherapy is FCM.Crossref, Medline, CAS, Google Scholar
• 36  Van Oers MHJ, Van Glabbeke M, Teodorovic I et al.: Chimeric anti-CD20 monoclonal antibody (rituximab; Mabthera) in remission induction and maintenance treatment of relapsed /resistant follicular non-Hodgkin's lymphoma: A Phase III randomized intergroup clinical trial. Blood104,169a [Abstract 586] (2004).Crossref, Google Scholar
• 37  Hochster HS, Weller E, Ryan T et al.: Results of E1496: A Phase III trial of CVP with or without maintenance with rituximab in advanced indolent lymphoma. Proc. Am. Soc. Clin. Oncol.556a [Abstract 6502] (2004).Google Scholar
• 38  Davis TA, Maloney DG, Grillo-Lopez AJ et al.: Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α2a. Clin. Can. Res.6(7), 2644–2652 (2000).Medline, CAS, Google Scholar
• 39  Kimby E: Beyond immunochemotherapy: Combinations of rituximab with cytokines interferon-α2a and granulocyte-macrophage colony stimulating factor. Sem. Oncol.29(2 Suppl. 6), 7–10 (2002).Crossref, Medline, CAS, Google Scholar
• 40  Eisenbeis CF, Grainger A, Fischer B et al.: Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and Phase I study. Clin. Cancer Res.10(18), 6101–6110 (2004).Crossref, Medline, CAS, Google Scholar
• 41  van der Kolk LE, de Haas M, Grillo-Lopez AJ, Baars JW, van Oers MHJ: Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils. Leukaemia16(4), 693–699 (2002).Crossref, Medline, CAS, Google Scholar
• 42  Foran JM, Rohatiner AZS, Cunningham D et al.: European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B cell lymphocytic lymphoma. J. Clin. Oncol. 18(2), 317–324 (2000).Crossref, Medline, Google Scholar
• 43  Hainsworth JD, Litchy S, Barton JH et al.: Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A Phase II trial of the Minnie Pearl Cancer Research Network. J. Clin. Oncol.21(9), 1746–1751 (2003).Crossref, Medline, CAS, Google Scholar
• 44  Keating M, Manshouri T, O'Brien S et al.: A high proportion of true complete remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukaemia. Blood2, 569 (2003).Google Scholar
• 45  Paydas S, Yavuz S, Disel U, Sahin B, Ergin M: Successful rituximab therapy for hemolytic anemia associated with relapsed splenic marginal zone lymphoma with leukemic phase. Leuk. Lymph.44(12), 2165–2166 (2003).Crossref, Medline, Google Scholar
• 46  Conconi A, Martinelli G, Thieblemont C et al.: Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood102(8), 2741–2745 (2003).Crossref, Medline, CAS, Google Scholar
• 47  Byrd JC, Murphy T, Howard RS et al.: Rituximab using a thrice-weekly dosing schedule in B-Cell chronic lymphocytic leukaemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol.19(8), 2153–2164 (2001).Crossref, Medline, CAS, Google Scholar
• 48  O'Brien SM, Kantarjian H, Thomas DA et al.: Rituximab dose-escalation trial in chronic lymphocytic leukaemia. J. Clin. Oncol.19(8), 2165–2170 (2001).Crossref, Medline, Google Scholar
• 49  Byrd JC, Peterson BL, Morrison VA et al.: Randomized Phase II study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B cell chronic lymphocytic leukaemia: results from Cancer and Leukaemia Group B 9712 (CALGB 9712). Blood101(1), 6–14 (2003).First description of the benefit of the combination of fludarabine with rituximab in patients with CLL.Crossref, Medline, CAS, Google Scholar
• 50  Byrd JC, Rai K, Peterson BL et al.: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukaemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood105(1), 49–53 (2005).A summary of the different studies with rituximab plus fludarabine in CLL patients.Crossref, Medline, CAS, Google Scholar
• 51  Feugier P, Hoof AV, Sebban C et al.: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B cell lymphoma. J. Clin. Oncol. 23 [In Press] (2005).Long-term follow-up of the GELA study having showed the benefit of combining rituximab to chemotherapy in lymphoma. This is a 5-year follow-up of R-CHOP compared to CHOP in elderly patients with diffuse large B-cell lymphoma.Medline, Google Scholar
• 52  Pfreundschuh MG, Trümper L, Ma D et al.: Randomized intergroup trial of first-line treatment for patients ≤ 60 years with diffuse large B cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab – early stopping after the first interim analysis. Proc. Am. Soc. Clin. Oncol.23, 556 [Abstract 6500] (2004).Google Scholar
• 53  Habermann TM, Weller E, Morrison VA et al.: Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): An update. Blood102, 6a[Abstract 8] (2004).Google Scholar
• 54  Sehn LH, Donaldson J, Chhanabhai M et al.: Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma (DLBC) in British Columbia (BC). Blood102 (Suppl. 1), 29a (2003).Google Scholar
• 55  Ekstrand BC, Lucas JB, Horwitz SM et al.: Rituximab in lymphocyte-predominant Hodgkin disease: results of a Phase II trial. Blood101(11), 4285–4289 (2003).Crossref, Medline, CAS, Google Scholar
• 56  Milpied N, Vasseur B, Parquet N et al.: Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann. Oncol.11(Suppl. 1), 113–116 (2000).Crossref, Medline, Google Scholar
• 57  Kaplan LD, Scadden DT: For the AIDS Malignancies Consortium. No benefit from rituximab in a randomized Phase III trial of CHOP with or without rituximab for patients with HIV-associated non-Hodgkin's lymphoma: AIDS malignancies consortium study 010. Proc. Am. Soc. Clin. Oncol. 22, 564 [Abstract 2268] (2004).Google Scholar
• 58  Gianni AM, Magni M, Martelli M et al.: Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood102(2), 749–755 (2003).Crossref, Medline, CAS, Google Scholar
• 59  Belhadj K, Delfau-Larue MH, Elgnaoui T et al.: Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study. Ann. Oncol.15(3), 504–510 (2004).Crossref, Medline, CAS, Google Scholar
• 60  Horwitz SM, Horning SJ: Rituximab in stem cell transplantation for aggressive lymphoma. Curr. Hematol. Rep.3(4), 227–229 (2004).Medline, Google Scholar
• 61  Brugger W: Clearing minimal residual disease with rituximab consolidation therapy. Semin. Oncol.31(1 Suppl. 2), 33–37 (2004).Crossref, Medline, CAS, Google Scholar
• 62  Lemieux B, Tartas S, Traulle C et al.: Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant. 33(9), 921–923 (2004).Crossref, Medline, CAS, Google Scholar
• 63  Coiffier B, Lepage E, Briere J et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl. J. Med.346(4), 235–242 (2002).First publication of the GELA study, first publication demonstrating the benefit of R-CHOP compared to CHOP only in patients with diffuse large B-cell lymphoma.Crossref, Medline, CAS, Google Scholar
• 64  Habermann TM, Weller EA, Morrison VA et al.: Phase III trial of rituximab-CHOP (R-CHOP) versus CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood 102(Suppl.1), 6a (2003).Google Scholar